<DOC>
	<DOCNO>NCT01707342</DOCNO>
	<brief_summary>The purpose study evaluate absolute bioavailability pharmacokinetics ( body medication ) simeprevir ( TMC435 ) administration single oral dos 50 mg 150 mg administer together single intravenous ( IV ) dose 100 microgram [ 3H ] -TMC435 healthy male participant .</brief_summary>
	<brief_title>A Study Assess Absolute Bioavailability Pharmacokinetics Simeprevir ( TMC435 ) Administered Single Oral Doses TMC435 Intravenous Microdose 3H-TMC435 Healthy Male Patients</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , sequential ( single group participant study medication administer sequence ) , single-dose study ass absolute bioavailability pharmacokinetics ( body medication ) single oral dos 50 mg 150 mg simeprevir ( TMC435 ) administer together intravenous ( IV ) microdose 100 microgram [ 3H ] -TMC435 healthy male participant . The study consist 3 phase , screen phase ( 21 day prior administration study medication ) , treatment phase , follow phase . In treatment phase , participant receive 2 treatment , ie , Treatment A : single oral dose simeprevir ( TMC435 ) 50 mg follow 5 hour later single 10 minute IV infusion [ 3H ] -TMC435 ( 100 microcurie ) 100 microgram ; Treatment B : single oral dose simeprevir ( TMC435 ) 150 mg follow 5 hour later single 10 minute IV infusion [ 3H ] -TMC435 ( 100 microcurie ) 100 microgram . Treatments administer two consecutive treatment period , first Treatment A Period 1 , follow Treatment B Period 2 ; separate washout period ( period participant receive study medication ) 7 14 day . The follow 5 7 day end Period 2 . Blood sample collect full plasma pharmacokinetics evaluation ; along urine stool sample analysis total plasma radioactivity . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , liver volume determination , specific toxicity monitor throughout study . The total duration study approximately 42 day .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram , clinical laboratory test perform screen Must nonsmoking least 3 month prior screen History liver renal insufficiency Have ferromagnetic medical implant medical device deprogrammed strong magnetic field , limit : cardiac pacemaker , implantable cardiac defibrillator , cochlear implant , insulin pump Had surgical intervention brain eye intraocular foreign metallic object Has history anxiety claustrophobia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy male participant</keyword>
	<keyword>Absolute bioavailability</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>TMC435</keyword>
	<keyword>[ 3H ] -TMC435</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>